Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2018-02-20 Remuneration Information
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
Corporate Governance Report - Oryzon Genomics S.A.
Remuneration Information Classification · 99% confidence The document is explicitly titled "INFORME ANUAL SOBRE REMUNERACIONES DE LOS CONSEJEROS DE SOCIEDADES ANONIMAS COTIZADAS" (Annual Report on Remuneration of Directors of Listed Public Limited Companies). It details the remuneration policy, the process for determining it, the composition of the Remuneration Committee, and the mix of compensation for the fiscal year ending 31/12/2017. This content directly corresponds to the definition of a report detailing compensation for top executives and directors, which maps to the 'Remuneration Information' category. Definition 26: Remuneration Information (Code: DEF 14A) - Report detailing compensation for top executives and directors. Although the content is about remuneration, which is often part of a 10-K or an Annual Report, the specific focus and title strongly suggest a dedicated report on this topic, which aligns best with DEF 14A (Proxy Statement/Information Statement, which often contains detailed remuneration reports in the US context, and this Spanish equivalent serves the same function for disclosure). Given the provided options, DEF 14A is the most specific fit for a detailed, standalone report on director remuneration policy and results, even if the document structure is Spanish regulatory in nature.
2018-02-20 Spanish
Annual Report 2017
Annual Report Classification · 100% confidence The document is titled 'Cuentas Anuales e Informe de Gestión' (Annual Accounts and Management Report) for Oryzon Genomics, S.A. for the fiscal year ending December 31, 2017. It contains detailed financial statements including the Balance Sheet, Profit and Loss Account, and Statement of Changes in Equity. As it represents the comprehensive annual financial reporting for the company, it is classified as an Annual Report (10-K equivalent). FY 2017
2018-02-20 Spanish
Annual Report 2016
Annual Report Classification · 95% confidence The document is a comprehensive financial report for Oryzon Genomics, S.A. for the fiscal year ending December 31, 2016. It includes the Balance Sheet, Profit and Loss Statement, and Statement of Changes in Equity. While the title mentions 'Cuentas Anuales' (Annual Accounts), which is the Spanish equivalent of an Annual Report, the content provided is the core financial statement component of the annual reporting package. Given the depth of the financial data provided, it is classified as an Annual Report (10-K equivalent). FY 2016
2017-02-27 Spanish
Corporate Governance Report - Oryzon Genomics S.A.
Remuneration Information Classification · 99% confidence The document is explicitly titled "INFORME ANUAL SOBRE REMUNERACIONES DE LOS CONSEJEROS DE SOCIEDADES ANONIMAS COTIZADAS" (Annual Report on Remuneration of Directors of Listed Public Limited Companies). It details the remuneration policy for directors for the years 2016-2018, the process for determining this policy, and the composition and role of the Appointments and Remuneration Committee. This content directly corresponds to the disclosure requirements for executive and director compensation, which is specifically covered by the DEF 14A filing category (Proxy Solicitation & Information Statement, often used for remuneration reports in certain jurisdictions, or more precisely, the Remuneration Information definition provided). Comparing with the definitions: - 10-K is too broad (Annual Report). - ER/IR are for financial results. - The document is a detailed report on remuneration, not just an announcement of a report (RPA/RNS) or a general governance report (CGR). - The definition for DEF 14A is "Report detailing compensation for top executives and directors." Given the specific focus on 'Remuneraciones de los Consejeros' (Director Remuneration), the most accurate classification is DEF 14A.
2017-02-24 Spanish
Corporate Governance Report - Oryzon Genomics S.A.
Remuneration Information Classification · 98% confidence The document is explicitly titled "INFORME ANUAL SOBRE REMUNERACIONES DE LOS CONSEJEROS DE SOCIEDADES ANONIMAS COTIZADAS" (Annual Report on Remuneration of Directors of Listed Companies). It details the remuneration policy (Política de Remuneraciones), the process for determining it, and the fixed components of remuneration for directors, referencing the fiscal year ending 31/12/2015. This content directly corresponds to the disclosure requirements for executive and director compensation, which aligns perfectly with the definition for Remuneration Information (DEF 14A), which is often used for proxy statements detailing compensation. Although the document discusses annual matters, its specific focus on remuneration policy and details makes DEF 14A (Proxy Solicitation & Information Statement, often containing remuneration details) a better fit than the general 10-K or the general governance report (CGR). In many jurisdictions, this specific report on director remuneration is a required standalone disclosure often filed alongside or as part of proxy materials.
2016-02-29 Spanish
Annual Report 2015
Annual Report Classification · 100% confidence The document is titled 'Cuentas Anuales e Informe de Gestión del ejercicio 2015' (Annual Accounts and Management Report for the 2015 fiscal year) for Oryzon Genomics, S.A. It contains detailed financial statements including the Balance Sheet, Profit and Loss Account, and Statement of Changes in Equity for the full fiscal year 2015. As it is a comprehensive annual financial report containing audited financial statements, it is classified as an Annual Report (10-K). FY 2015
2016-02-29 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.